CoChat
Cited by 169

The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.

BRAF Mutant Gastrointestinal Stromal Tumor: First report of regression with BRAF inhibitor dabrafenib (GSK2118436) and whole exomic sequencing for analysis of acquired resistance

Open access
Falchook, G.S., Trent, J.C., Heinrich, M.C., Beadling, C., Patterson, J., Bastida, C.C., Blackman, S.C., Kurzrock, R. · 2013 · Oncotarget

Abstract

// G.S. Falchook 1 , J.C. Trent 2 , M.C. Heinrich 3 , C. Beadling 3 , J. Patterson 3 , C.C. Bastida 1 , S.C. Blackman 4 , R. Kurzrock 5 1 Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), Division of Cancer Medicine, The University of Texas M.D. Anderson Cancer Center, Houston, Texas 2 Sarcoma Medical Oncology Program, University of Miami, Sylvester Comprehensive Cancer Center, Miami, Florida 3 Portland VA Medical Center and Oregon Health & Science University (OHSU) Knight Cancer Institute, Division of Hematology & Oncology, Portland, Oregon 4 GlaxoSmithKline, Collegeville, PA 5 Moores Cancer Center, Department of Medicine, Hematology-Oncology Division, The University of California, San Diego, La Jolla, CA Correspondence: Gerald Falchook, email: // Keywords : Gastrointestinal stromal tumor, Dabrafenib, GSK2118436, BRAF mutation, BRAF inhibition, V600E Received : February 8, 2013 Accepted : February 24, 2013 Published : February 25, 2013 Abstract Activating oncogenic mutations of BRAF have been described in patients with gastrointestinal stromal tumor (GIST), but treatment of GIST with BRAF inhibitors and mechanisms of mediating the emergence of resistance in GIST have not been reported. Dabrafenib is a potent ATP-competitive inhibitor of BRAF kinase and is highly selective for mutant BRAF in kinase panel screening, cell lines, and xenografts. We report prolonged antitumor activity in the first patient with V600E BRAF-mutated GIST who was treated with a BRAF inhibitor. Whole exome sequencing performed in tumor tissue obtained at the time of progressive disease demonstrated a somatic gain-of-function PIK3CA mutation (H1047R) as well as a CDKN2A aberration, which may have contributed to eventual resistance to treatment.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.18632/oncotarget.864

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 169

Metadata

Authors
Falchook, G. S., Trent, J. C., Heinrich, M. C., Beadling, C., Patterson, J., Bastida, C. C., Blackman, S. C., & Kurzrock, R.
Venue
Oncotarget
Published
2013-02-25
Volume
4
Issue
2
Pages
310-315
ISSN
1949-2553 (ISSN-L)
OpenAlex
W2157539391
Cited by
169
References
7
FWCI
14.77
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.